Literature DB >> 7575616

Interleukin-1 and oncostatin M in combination promote the release of collagen fragments from bovine nasal cartilage in culture.

T E Cawston1, A J Ellis, G Humm, E Lean, D Ward, V Curry.   

Abstract

Interleukin-1 (IL-1) and Oncostatin M (OM) induce a rapid and reproducible release of proteoglycan and collagen fragments from bovine nasal cartilage in culture. Over 90% of the total collagen was released by day 14 compared to a variable release with IL-1 alone. This release was accompanied by the appearance of collagenolytic activity in the medium that cleaved collagen specifically at the one quarter/three quarter position. Tissue inhibitor of metalloproteinases (TIMP-1) activity was low or absent in media from resorbing tissue. The breakdown of cartilage collagen could be prevented by the addition of BB94, a specific matrix metalloproteinase (MMP) inhibitor. These results suggest that T-cell/macrophage products within inflammed joints can interact with pro-inflammatory cytokines and lead to the rapid destruction of connective tissue collagen.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7575616     DOI: 10.1006/bbrc.1995.2476

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  17 in total

1.  Murine oncostatin M stimulates mouse synovial fibroblasts in vitro and induces inflammation and destruction in mouse joints in vivo.

Authors:  C Langdon; C Kerr; M Hassen; T Hara; A L Arsenault; C D Richards
Journal:  Am J Pathol       Date:  2000-10       Impact factor: 4.307

2.  Dual regulation of metalloproteinase expression in chondrocytes by Wnt-1-inducible signaling pathway protein 3/CCN6.

Authors:  Natasha Baker; Paul Sharpe; Kirsty Culley; Miguel Otero; Damon Bevan; Peter Newham; Wendy Barker; Kristen M Clements; Caroline J Langham; Mary B Goldring; Jelena Gavrilović
Journal:  Arthritis Rheum       Date:  2012-07

3.  Aggrecan and cartilage oligomeric matrix protein in serum and synovial fluid of patients with knee osteoarthritis.

Authors:  Mohammed M El-Arman; Ghada El-Fayoumi; Elwaleid El-Shal; Ibrahim El-Boghdady; Atef El-Ghaweet
Journal:  HSS J       Date:  2010-03-02

4.  An aggrecan-degrading activity associated with chondrocyte membranes.

Authors:  C J Billington; I M Clark; T E Cawston
Journal:  Biochem J       Date:  1998-11-15       Impact factor: 3.857

5.  Interleukin 13 blocks the release of collagen from bovine nasal cartilage treated with proinflammatory cytokines.

Authors:  C S Cleaver; A D Rowan; T E Cawston
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

6.  Esculetin inhibits cartilage resorption induced by interleukin 1alpha in combination with oncostatin M.

Authors:  S Elliott; A D Rowan; S Carrère; P Koshy; J B Catterall; T E Cawston
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

7.  Collagenolytic matrix metalloproteinases antagonize proteinase-activated receptor-2 activation, providing insights into extracellular matrix turnover.

Authors:  Adrian M D Falconer; Chun Ming Chan; Joseph Gray; Izuru Nagashima; Robert A Holland; Hiroki Shimizu; Andrew R Pickford; Andrew D Rowan; David J Wilkinson
Journal:  J Biol Chem       Date:  2019-05-19       Impact factor: 5.157

8.  Stromelysin 1, neutrophil collagenase, and collagenase 3 do not play major roles in a model of chondrocyte mediated cartilage breakdown.

Authors:  L D Kozaci; C J Brown; C Adcocks; A Galloway; A P Hollander; D J Buttle
Journal:  Mol Pathol       Date:  1998-10

9.  Human nasal cartilage responds to oncostatin M in combination with interleukin 1 or tumour necrosis factor alpha by the release of collagen fragments via collagenases.

Authors:  T G Morgan; A D Rowan; S C Dickinson; D Jones; A P Hollander; D Deehan; T E Cawston
Journal:  Ann Rheum Dis       Date:  2005-06-23       Impact factor: 19.103

10.  An exploration of the ability of tepoxalin to ameliorate the degradation of articular cartilage in a canine in vitro model.

Authors:  Lisa Macrory; Anne Vaughan-Thomas; Peter D Clegg; John F Innes
Journal:  BMC Vet Res       Date:  2009-07-22       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.